Noticias - profesionales

1	Zeltia reports that its subsidiary Sylentis presented two posters based on its research on interference RNA at the World Glaucoma Congress 2011	04/07/2011
2	Zeltia subsidiary Sylentis commences Phase I trials with its new compound SYL1001 to treat eye pain associated with dry eye syndrome	06/06/2011
3	Sylentis - Treatment commences for first patients in Phase I/II clinical trial with SYL040012	22/11/2010
4	Sylentis receives authorisation to commence a new Phase I/IIclinical trial with SYL040012 for treating elevated intraocular pressure and glaucoma	06/09/2010
5	Sylentis completes Phase I trial with SYL040012 to treat elevated intraocular pressure and glaucoma	06/07/2010
6	RNA interference Technologies and Therapeutics	22/09/2009
7	Sylentis Receives Approval to Begin Clinical Trial With SYL040012 for Ocular Hypertension Associated To Glaucoma	22/07/2009
8	Sylentis presents results in ARVO 2009	22/05/2009
9	RNA interference-based therapeutics: new strategies to fight infectious disease	15/12/2008
10	Sylentis presents scientific results at ARVO 2008	05/05/2008

RSS